title: Naftopidil monotherapy vs naftopidil and an anticholinergic agent combined therapy for storage symptoms associated with benign prostatic hyperplasia: A prospective randomized controlled study.
abstract: OBJECTIVE
  The aim of this study was to compare the efficacy and safety of alpha1-adrenoceptor (alpha1-AR) antagonist monotherapy with combination therapy using alpha1-AR antagonist and anticholinergic agent for benign prostatic hyperplasia (BPH) with storage symptoms as the chief complaint.
  
  
  METHODS
  In this prospective comparative study, either 25-75 mg/day of naftopidil monotherapy (monotherapy group) or combination therapy using 25-75 mg/day of naftopidil and an anticholinergic agent (10-20 mg/day of propiverine hydrochloride or 2-6 mg/day of oxybutynin hydrochloride; cotherapy group) were administered for 12 weeks to 101 BPH patients with storage symptoms.
  
  
  RESULTS
  International prostate symptom score (IPSS) and quality of life (QOL) index improved significantly in both groups, with no marked differences between groups. Maximum flow rate (Qmax) and residual urine volume (RUV) tended to improve in both groups, again with no marked differences between groups. However, median post-therapeutic RUV was significantly worse for the cotherapy group (45.0 mL) than for the monotherapy group (13.5 mL; P = 0.0210). Ratio of patients with increased RUV was also significantly worse for cotherapy (22.9%) than for monotherapy (5.0%; P = 0.038).
  
  
  CONCLUSIONS
  Although the anticholinergic dosage was low, the present results suggest that naftopidil monotherapy was as useful as combination therapy of naftopidil and an anticholinergic agent. Therefore, naftopidil is a useful agent as the first choice in BPH patients with storage symptoms.
authors.affiliation: Department of Urology, Juntendo University Urayasu Hospital, Tomioka Urayasu, Chiba, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Maruyama
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Kawachi
authors.forename: Kisaburo
authors.initials: K
authors.lastname: Hanazawa
authors.forename: Kazuo
authors.initials: K
authors.lastname: Koizumi
authors.forename: Ryo
authors.initials: R
authors.lastname: Yamashita
authors.forename: Sosuke
authors.initials: S
authors.lastname: Sugimura
authors.forename: Shin-ichi
authors.initials: S
authors.lastname: Honda
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Sugiyama
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Saitoh
authors.forename: Kensho
authors.initials: K
authors.lastname: Noto
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D001561:Benzilates / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use; D009281:Naphthalenes / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000150:complications*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D014563:Urodynamics / Q000187:drug effects
chemical_list: D000317:Adrenergic alpha-Antagonists; D001561:Benzilates; D018680:Cholinergic Antagonists; D008333:Mandelic Acids; D009281:Naphthalenes; D010879:Piperazines; C015586:propiverine; C005419:oxybutynin; C064357:naftopidil